<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613079</url>
  </required_header>
  <id_info>
    <org_study_id>TRIFRA</org_study_id>
    <nct_id>NCT01613079</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>TRIFRA</acronym>
  <official_title>Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the
      treatment of RA patients with clinical efficacy and safety.Open-labeled, randomized,
      prospective multi-center clinical trial. Observation period of 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR50</measure>
    <time_frame>24 weeks.</time_frame>
    <description>The proportion of patients achieving ACR50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiology outcome</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in X-Ray from baseline to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in DAS score from baseline to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR20/70</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of patients achieving ACR20 &amp; ACR70.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were treated with methotrexate alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX+T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients were treated with methotrexate and T2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium wilfordii Hook F</intervention_name>
    <description>Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.</description>
    <arm_group_label>T2</arm_group_label>
    <arm_group_label>MTX+T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>MTX+T2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years with informed consent

          -  Diagnosed with rheumatoid arthritis as determined by meeting the 2010 ACR/EULAR
             classification criteria and has had rheumatoid arthritis for at least 6 weeks

          -  Swollen joint (SJC)≥3 and tender joint count(TJC)≥5

          -  ESR &gt;28 mm/hr or C-reactive protein &gt; 20 mg/L

        Exclusion Criteria:

          -  Pregnant, lactating or further fertility requirements

          -  Previous treated with methotrexate or biologic DMARD.

          -  Active or chronic infection, including HIV, HCV, HBV, tuberculosis

          -  Patient with cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuan Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Xuan Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Tripterygium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

